Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Candel Therapeutics, Inc. (CADL) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Candel Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1841387.
Total stock buying since 2021: $9,321,785.
Total stock sales since 2021: $4,138,715.
Total stock option exercises since 2021: $544,218.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 281,289 | $2,317,577 | 38,207 | $76,707 |
| 2024 | 1,250,000 | $7,500,000 | 317,792 | $1,821,138 | 12,900 | $19,995 |
| 2022 | 1,238 | $1,993 | 0 | $0 | 306,518 | $447,516 |
| 2021 | 232,125 | $1,819,792 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-07 | 0 | $0 | 937 | $6,540 | 937 | $1,208 |
| 2025-06 | 0 | $0 | 781 | $3,936 | 781 | $1,007 |
| 2025-03 | 0 | $0 | 139,912 | $1,228,401 | 36,489 | $74,492 |
| 2025-01 | 0 | $0 | 139,659 | $1,078,700 | 0 | $0 |
| 2024-12 | 1,250,000 | $7,500,000 | 0 | $0 | 0 | $0 |
| 2024-11 | 0 | $0 | 105,255 | $479,539 | 12,900 | $19,995 |
| 2024-10 | 0 | $0 | 75,414 | $486,473 | 0 | $0 |
| 2024-07 | 0 | $0 | 137,123 | $855,126 | 0 | $0 |
| 2022-12 | 1,238 | $1,993 | 0 | $0 | 0 | $0 |
| 2022-05 | 0 | $0 | 0 | $0 | 306,518 | $447,516 |
| 2021-07 | 232,125 | $1,819,792 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-07-28 | Nichols William Garrett (Chief Medical Officer) | Sale | 937 | 6.98 | 6,540 |
| 2025-07-28 | Nichols William Garrett (Chief Medical Officer) | Option Ex | 937 | 1.29 | 1,208 |
| 2025-06-30 | Nichols William Garrett (Chief Medical Officer) | Sale | 781 | 5.04 | 3,936 |
| 2025-06-30 | Nichols William Garrett (Chief Medical Officer) | Option Ex | 781 | 1.29 | 1,007 |
| 2025-03-19 | Tak Paul Peter (Chief Executive Officer) | Sale | 400 | 9.00 | 3,601 |
| 2025-03-18 | Barone Francesca (Chief Scientific Officer) | Sale | 32,146 | 8.76 | 281,663 |
| 2025-03-18 | Barone Francesca (Chief Scientific Officer) | Option Ex | 18,000 | 1.55 | 27,900 |
| 2025-03-18 | Tak Paul Peter (Chief Executive Officer) | Sale | 25,772 | 8.77 | 226,020 |
| 2025-03-18 | Nichols William Garrett (Chief Medical Officer) | Sale | 45,316 | 8.76 | 397,013 |
| 2025-03-18 | Nichols William Garrett (Chief Medical Officer) | Option Ex | 18,489 | 2.52 | 46,592 |
| 2025-03-17 | Schoch Charles (See Remarks) | Sale | 5,000 | 8.83 | 44,170 |
| 2025-03-17 | Tyagarajan Seshu (Chief Technology Officer) | Sale | 31,278 | 8.82 | 275,934 |
| 2025-01-15 | Schoch Charles (See Remarks) | Sale | 9,511 | 7.22 | 68,716 |
| 2025-01-15 | Tyagarajan Seshu (Chief Technology Officer) | Sale | 14,322 | 7.22 | 103,476 |
| 2025-01-15 | Barone Francesca (Chief Scientific Officer) | Sale | 13,534 | 7.22 | 97,783 |
| 2025-01-15 | Tak Paul Peter (Chief Executive Officer) | Sale | 21,704 | 7.22 | 156,811 |
| 2025-01-15 | Nichols William Garrett (Chief Medical Officer) | Sale | 10,428 | 7.22 | 75,342 |
| 2025-01-08 | Schoch Charles (See Remarks) | Sale | 9,971 | 8.22 | 81,941 |
| 2025-01-08 | Tyagarajan Seshu (Chief Technology Officer) | Sale | 14,545 | 8.22 | 119,530 |
| 2025-01-08 | Barone Francesca (Chief Scientific Officer) | Sale | 13,673 | 8.22 | 112,364 |
| 2025-01-08 | Tak Paul Peter (Chief Executive Officer) | Sale | 21,172 | 8.22 | 173,991 |
| 2025-01-08 | Nichols William Garrett (Chief Medical Officer) | Sale | 10,799 | 8.22 | 88,746 |
| 2024-12-16 | Manning Paul B | Buy | 1,250,000 | 6.00 | 7,500,000 |
| 2024-11-29 | Tyagarajan Seshu (Chief Technology Officer) | Sale | 20,392 | 4.56 | 92,905 |
| 2024-11-29 | Barone Francesca (Chief Scientific Officer) | Sale | 22,081 | 4.56 | 100,601 |
| 2024-11-29 | Tak Paul Peter (Chief Executive Officer) | Sale | 48,847 | 4.56 | 222,546 |
| 2024-11-29 | Nichols William Garrett (Chief Medical Officer) | Sale | 13,935 | 4.56 | 63,487 |
| 2024-11-21 | Tak Paul Peter (Chief Executive Officer) | Option Ex | 12,900 | 1.55 | 19,995 |
| 2024-10-15 | Aguilar Laura K. (10% Owner) | Sale | 10,412 | 6.03 | 62,784 |
| 2024-10-14 | Aguilar Laura K. (10% Owner) | Sale | 15,000 | 6.02 | 90,300 |
| 2024-10-11 | Aguilar Laura K. (10% Owner) | Sale | 15,000 | 6.05 | 90,750 |
| 2024-10-03 | Aguilar Laura K. (10% Owner) | Sale | 1,800 | 6.85 | 12,330 |
| 2024-10-02 | Aguilar Laura K. (10% Owner) | Sale | 26,988 | 6.92 | 186,756 |
| 2024-10-01 | Aguilar Laura K. (10% Owner) | Sale | 6,214 | 7.01 | 43,553 |
| 2024-07-17 | Schoch Charles (See Remarks) | Sale | 9,884 | 6.47 | 63,979 |
| 2024-07-17 | Tyagarajan Seshu (Chief Technology Officer) | Sale | 14,851 | 6.47 | 96,130 |
| 2024-07-17 | Barone Francesca (Chief Scientific Officer) | Sale | 14,051 | 6.47 | 90,952 |
| 2024-07-17 | Tak Paul Peter (Chief Executive Officer) | Sale | 22,528 | 6.47 | 145,823 |
| 2024-07-17 | Nichols William Garrett (Chief Medical Officer) | Sale | 10,875 | 6.47 | 70,393 |
| 2024-07-11 | Schoch Charles (See Remarks) | Sale | 8,897 | 5.97 | 53,141 |
| 2024-07-11 | Tyagarajan Seshu (Chief Technology Officer) | Sale | 13,330 | 5.97 | 79,620 |
| 2024-07-11 | Barone Francesca (Chief Scientific Officer) | Sale | 12,645 | 5.97 | 75,528 |
| 2024-07-11 | Tak Paul Peter (Chief Executive Officer) | Sale | 20,293 | 5.97 | 121,210 |
| 2024-07-11 | Nichols William Garrett (Chief Medical Officer) | Sale | 9,769 | 5.97 | 58,350 |
| 2022-12-08 | Barone Francesca (Chief Scientific Officer) | Buy | 1,238 | 1.61 | 1,993 |
| 2022-05-06 | Aguilar-cordova Estuardo (Director) | Option Ex | 135,183 | 1.46 | 197,367 |
| 2022-05-06 | Aguilar Laura K. (10% Owner) | Option Ex | 171,335 | 1.46 | 250,149 |
| 2021-07-29 | Tak Paul Peter (Chief Executive Officer) | Buy | 25,000 | 8.00 | 200,000 |
| 2021-07-29 | Martell Christopher (Director) | Buy | 125,000 | 8.00 | 1,000,000 |
| 2021-07-29 | Caffo Nathan (Chief Business Officer) | Buy | 6,000 | 8.00 | 48,000 |
| 2021-07-29 | Nguyen Diem (Director) | Buy | 10,000 | 8.00 | 80,000 |
| 2021-07-29 | Canepa John J (Chief Financial Officer) | Buy | 10,125 | 8.00 | 81,000 |
| 2021-07-29 | Manning Paul B (Director) | Buy | 20,000 | 7.30 | 145,940 |
| 2021-07-27 | Manning Paul B (Director) | Buy | 36,000 | 7.36 | 264,852 |
Insider trading activities including stock purchases, stock sales, and option exercises of CADL listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Candel Therapeutics, Inc. (symbol CADL, CIK number 1841387) see the Securities and Exchange Commission (SEC) website.